Author + information
We aimed to test the efficacy and safety of 6-month and 12-month DAPT after implantation of BP-SES in elder patients.
In the I-LOVE-IT 2 Trial, 627 patients with age≥65 were Implanted with BP-SES, of whom 319 were randomized to follow a 6-month DAPT and 308 to follow a 12-month DAPT after the index PCI. The primary end points was 12-month target lesion failure (TLF, composite of cardiac death, target vessel myocardial infarction or clinically indicated target lesion revascularization), and the secondary end points were 12-month net adverse clinical and cerebral events (NACE, composite of all-cause death, all myocardial infarction, stroke, or all bleeding) and its components.
Rates of TLF at 12 months were 7.2% in the 6-month DAPT group and 7.1% in the 12-month DAPT group with no significant difference(P=0.97). Moreover, no differences were observed in NACE at 12 months between 6-months DAPT and 12-months DAPT (14.4% versus 13.0%, P=0.73). There were no significant difference in stent thrombosis or bleeding complications in between the two groups.
This study indicated that compared with 12-month DAPT, 6-month DAPT did not increase the risk of 12-month TLF in elder patients after implantation of BP-SES.